Table 3.
ADXS31-142 treatment-related AEs reported in >2 patients in any treatment arm.
| Preferred term | No. of patients (%) | |
|---|---|---|
| ADXS31-142 monotherapy (n = 13) |
ADXS31-142 + pembrolizumab (n = 37) |
|
| Patients with at least 1 AE | 13 (100.0) | 37 (100.0) |
| Chills | 10 (76.9) | 33 (89.2) |
| Pyrexia | 8 (61.5) | 20 (54.1) |
| Hypotension | 6 (46.2) | 8 (21.6) |
| Nausea | 5 (38.5) | 17 (45.9) |
| Fatigue | 5 (38.5) | 13 (35.1) |
| Hypertension | 2 (15.4) | 9 (24.3) |
| Vomiting | 2 (15.4) | 5 (13.5) |
| Tachycardia | 2 (15.4) | 4 (10.8) |
| Decreased appetite | 1 (7.7) | 6 (16.2) |
| Anemia | 1 (7.7) | 5 (13.5) |
| Headache | 1 (7.7) | 5 (13.5) |
| Diarrhea | 1 (7.7) | 4 (10.8) |
| Pain | 1 (7.7) | 4 (10.8) |
| Hypothyroidism | 0 | 7 (18.9) |
| Thrombocytopenia | 0 | 3 (8.1) |
| Back pain | 0 | 3 (8.1) |
| Hypoxia | 0 | 3 (8.1) |
| Rash | 0 | 3 (8.1) |
Abbreviation: AE, adverse event.